Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
03:54:47 EDT Tue 13 May 2025
Enter Symbol
or Name
USA
CA



Q:ATOS - ATOSSA THERAPEUTICS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
ATOS - Q0.10.7682·0.92650.10.8369+0.02022.5552.43541,4770.86  0.8603  0.83021.71  0.5526May 12Apr 3015 min RT 2¢

Recent Trades - Last 10 of 1477
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-04-30 08:45U:ATOSNews ReleaseAtossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio
2025-04-29 08:45U:ATOSNews ReleaseAtossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025
2025-04-22 08:45U:ATOSNews ReleaseAtossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio
2025-04-10 08:00U:ATOSNews ReleaseNona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer
2025-03-25 08:00U:ATOSNews ReleaseAtossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update
2025-03-20 09:13U:ATOSNews ReleaseAtossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
2025-03-11 08:15U:ATOSNews ReleaseAtossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications
2025-02-05 08:00U:ATOSNews ReleaseAtossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care
2025-01-30 08:17U:ATOSNews ReleaseAtossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No. 12,201,591
2025-01-23 08:15U:ATOSNews ReleaseAtossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025
2025-01-06 09:00U:ATOSNews ReleaseAtossa Therapeutics Applauds U.S. Surgeon General's Advisory Highlighting Alcohol as a Leading Preventable Cause of Breast Cancer
2024-12-12 08:15U:ATOSNews ReleaseAtossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium
2024-12-11 08:15U:ATOSNews ReleaseAtossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density
2024-12-10 09:05U:ATOSNews ReleaseAtossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium
2024-12-09 08:15U:ATOSNews ReleaseAtossa Therapeutics Presents Data from Study Investigating Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds at AACR Special Conference in Cancer Research
2024-11-21 08:30U:ATOSNews ReleaseAtossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research
2024-11-20 08:30U:ATOSNews ReleaseAtossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium
2024-11-12 08:30U:ATOSNews ReleaseAtossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
2024-11-05 08:30U:ATOSNews ReleaseAtossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development
2024-11-04 06:30U:ATOSNews ReleaseAtossa Therapeutics Reports Positive KARISMA-Endoxifen Trial Results: